CareLit · DOI-Nachweis · Pneumologie
ALINA: a phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB-IIIA anaplastic lymphoma kinase-positive (ALK +) non-small cell cancer (NSCLC)
DOI 10.1055/s-0039-3403357
Bibliografische Angaben
Nachweis in CareLit
Autor:innenA Rittmeyer, B Solomon, JS Ahn, F Barlesi, R Dziadziuszko, M Nishio, A Shaw, W Bordogna, C Meyenberg, YL Wu
ZeitschriftPneumologie
AusgabeS 01 S 01/2020
Jahrgang / SeitenJg. 74
Kernaussage aus der Literatur
Abstract-Vorschau
ALINA: a phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB-IIIA anaplastic lymphoma kinase-positive (ALK +) non-small cell cancer (NSCLC)
Zitieren
Zitierempfehlung
A Rittmeyer, B Solomon, JS Ahn, F Barlesi, R Dziadziuszko, M Nishio, A Shaw, W Bordogna, C Meyenberg, YL Wu (2020) ALINA: a phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB-IIIA anaplastic lymphoma kinase-positive (ALK +) non-small cell cancer (NSCLC). Pneumologie, 74 (S 01 S 01). https://doi.org/10.1055/s-0039-3403357
Mit CareLit weiterarbeiten